Gilead Sciences, Inc. $GILD Shares Bought by Rosenberg Matthew Hamilton

Rosenberg Matthew Hamilton raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,522 shares of the biopharmaceutical company’s stock after acquiring an additional 304 shares during the quarter. Rosenberg Matthew Hamilton’s holdings in Gilead Sciences were worth $280,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GILD. Mutual Advisors LLC raised its stake in shares of Gilead Sciences by 16.9% during the 2nd quarter. Mutual Advisors LLC now owns 21,228 shares of the biopharmaceutical company’s stock worth $2,467,000 after buying an additional 3,072 shares during the last quarter. Ritholtz Wealth Management raised its stake in shares of Gilead Sciences by 12.4% during the 2nd quarter. Ritholtz Wealth Management now owns 115,166 shares of the biopharmaceutical company’s stock worth $12,768,000 after buying an additional 12,726 shares during the last quarter. Sagespring Wealth Partners LLC raised its stake in shares of Gilead Sciences by 28.5% during the 2nd quarter. Sagespring Wealth Partners LLC now owns 17,351 shares of the biopharmaceutical company’s stock worth $1,924,000 after buying an additional 3,848 shares during the last quarter. TD Asset Management Inc raised its stake in shares of Gilead Sciences by 44.7% during the 2nd quarter. TD Asset Management Inc now owns 3,420,676 shares of the biopharmaceutical company’s stock worth $379,250,000 after buying an additional 1,056,474 shares during the last quarter. Finally, Revolve Wealth Partners LLC raised its stake in shares of Gilead Sciences by 3.1% during the 2nd quarter. Revolve Wealth Partners LLC now owns 3,595 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 108 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,000 shares of company stock valued at $7,632,100 in the last three months. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Cantor Fitzgerald lifted their price objective on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a report on Wednesday, October 8th. Finally, Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a report on Friday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $118.08.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $118.30 on Thursday. The business’s 50-day simple moving average is $115.00 and its 200-day simple moving average is $110.41. The firm has a market capitalization of $146.79 billion, a P/E ratio of 23.57, a P/E/G ratio of 0.81 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $85.60 and a 1-year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the company posted $2.01 EPS. Gilead Sciences’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.